INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IN8BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.09−0.02 (-1.80%)
Close on Oct 19, 2026
- Market cap
- $21.22M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
38.4%
4M of 10M shares
Institutional holders
21
3 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lytton Laurence W | 984,031 | 9.99% | 13G (passive) | Dec 22, 2025 |
| Alyeska Investment Group, L.P. | 966,381 | 9.90% | 13G (passive) | Dec 31, 2025 |
| Franklin Advisers, Inc. | 914,531 | 9.40% | 13G (passive) | Dec 31, 2025 |
| Bios Advisors Gp, LLC | 9,120,073 | 9.90% | 13D (active) amendment | May 2, 2025 |
| 683 Capital Management, LLC | 770,445 | 7.86% | 13G (passive) | Dec 22, 2025 |
| Lytton-Kambara Foundation | 1,056,513 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Stonepine Capital, L.P. | 1,007,990 | 9.90% | 13G (passive) | Dec 19, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INAB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 944,319 | 9.58% | $1.33M | – | 0.00% |
| Franklin Resources Inc | 914,531 | 9.28% | $1.29M | – | 0.00% |
| 683 Capital Management, LLC | 724,637 | 7.35% | $1.02M | – | 0.05% |
| Stonepine Capital Management, LLC | 695,287 | 7.05% | $980.36K | +31,875 | 0.55% |
| Vanguard Capital Management LLC | 88,865 | 0.90% | $126.54K | – | 0.00% |
| BIOS Capital Management, LP | 80,957 | 0.82% | $114.15K | −86,848 | 0.27% |
| Geode Capital Management, LLC | 72,550 | 0.74% | $102.30K | −13,689 | 0.00% |
| Citadel Advisors LLC | 63,055 | 0.64% | $88.91K | New | 0.00% |
| Oppenheimer & Co Inc | 63,042 | 0.64% | $88.89K | +39,009 | 0.00% |
| Vanguard Fiduciary Trust Co | 43,570 | 0.44% | $62.04K | – | 0.00% |
| Captrust Financial Advisors | 33,295 | 0.34% | $46.95K | – | 0.00% |
| Texas Capital Bank Wealth Management Services Inc | 24,406 | 0.25% | $34.41K | +656 | 0.00% |
| Northern Trust Corp | 21,734 | 0.22% | $30.65K | +1,294 | 0.00% |
| Renaissance Technologies LLC | 12,100 | 0.12% | $17.06K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 3,738 | 0.04% | $5.27K | +2,473 | 0.00% |
| Northwestern Mutual Wealth Management Co | 2,785 | 0.03% | $3.93K | – | 0.00% |
| Jones Financial Companies Lllp | 768 | 0.01% | $1.04K | – | 0.00% |
| BlackRock, Inc. | 84 | 0.00% | $118 | – | 0.00% |
| Rockefeller Capital Management L.P. | 83 | 0.00% | $117 | – | 0.00% |
| Barclays PLC | 28 | 0.00% | $39 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 21 | 4M | 38.4% | 3 / 5 | 3 / 1 | 0M | 0M |
| Q1 2026 | 19 | 4M | 38.1% | 3 / 4 | 6 / 5 | 1M | 0M |
| Q4 2025 | 22 | 3M | 32.7% | 8 / 7 | 5 / 4 | 3M | 0M |
| Q3 2025 | 18 | 1M | 7.0% | 8 / 4 | 3 / 1 | 0M | 0M |
| Q2 2025 | 11 | 1M | 6.0% | 11 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of INAB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Franklin Biotechnology Discovery Fund | 332,083 | 3.37% | $345.37K | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 88,865 | 0.90% | $125.30K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 63,611 | 0.65% | $118.95K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 8,320 | 0.08% | $15.56K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,040 | 0.02% | $3.81K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 567 | 0.01% | $1.06K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 200 | 0.00% | $282 | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 0 | 0.00% | $0 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William Tai-Wei Ho | CEO, Director | 124,817 | 1.27% | May 12, 2026 |
| Kate Rochlin | President and COO | 9,085 | 0.09% | May 12, 2026 |
| Patrick McCall | CHIEF FINANCIAL OFFICER | 9,482 | 0.10% | May 12, 2026 |
| Lawrence Lamb | EVP and CSO | 101,369 | 1.03% | May 12, 2026 |
| Emily Fairbairn | Director | 0 | – | May 29, 2026 |
| Luba Greenwood | Director | 7,826 | 0.08% | May 12, 2026 |
| Peter C. Brandt | Director | 98,690 | 1.00% | May 12, 2026 |
| Jeremy R. Graff | Director | 4,549 | 0.05% | May 12, 2026 |
| Corinne Epperly | Director | 81,967 | 0.83% | May 12, 2026 |
| Alan S. Roemer | Director | 49,514 | 0.50% | Dec 23, 2025 |
| Travis Whitfill | Director | – | – | Dec 23, 2024 |
| BIOS Advisors GP, LLC | 10% owner | 540,287 | 5.48% | May 7, 2025 |
| BIOS Fund II QP, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| BIOS Fund II NT, LP | 10% owner | 561,989 | 5.70% | May 7, 2025 |
| BP Directors, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| Cavu Advisors, LLC | 10% owner | 559,076 | 5.67% | May 7, 2025 |
| BIOS Incysus Co-Invest I, LP | 10% owner | – | – | May 7, 2025 |
| BIOS Equity Partners III, LP | 10% owner | – | – | May 7, 2025 |
| BIOS Fund III, LP | 10% owner | – | – | May 7, 2025 |
| BIOS Fund III QP, LP | 10% owner | 570,724 | 5.79% | May 7, 2025 |
| BIOS Fund III NT, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| Cavu Management, LP | 10% owner | 3,612,569 | 36.64% | May 7, 2025 |
| Leslie W. Kreis | 10% owner | 570,724 | 5.79% | May 7, 2025 |
| Aaron G.L. Fletcher | 10% owner | – | – | May 7, 2025 |
| Bios Equity COF, LP | 10% owner | – | – | May 7, 2025 |
| Bios Clinical Opportunity Fund, LP | 10% owner | – | – | May 7, 2025 |
| Bios Equity Partners II, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| BIOS Fund II, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| BIOS Capital Management, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| Bios Equity Partners, LP | 10% owner | – | – | May 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Emily Fairbairn Director | May 27, 2026 | Gift | −724,637 | – | – | 0 |
| Peter C. Brandt Director | Dec 22, 2025 | Award | +72,464 | $1.38 | $100.00K | 95,181 |
| Patrick McCall CHIEF FINANCIAL OFFICER | Dec 22, 2025 | Award | +7,247 | $1.38 | $10.00K | 9,482 |
| William Tai-Wei Ho PRESIDENT AND CEO, Director, 10% owner | Dec 22, 2025 | Award | +36,232 | $1.38 | $50.00K | 121,168 |
| Emily Fairbairn Director | Dec 22, 2025 | Award | +724,637 | $1.38 | $1,000.00K | 724,637 |
| Kate Rochlin Chief Operating Officer | Dec 22, 2025 | Award | +7,247 | $1.38 | $10.00K | 9,085 |
| Alan S. Roemer Director | Dec 22, 2025 | Award | +36,232 | $1.38 | $50.00K | 49,514 |
| Peter C. Brandt Director | Apr 30, 2025 | Option exercise | +81,967 | $0.18 | $14.75K | 681,538 |
| Peter C. Brandt Director | Apr 30, 2025 | Option exercise | +81,967 | $0.18 | $14.75K | 599,571 |
| Patrick McCall CHIEF FINANCIAL OFFICER | Apr 30, 2025 | Option exercise | +15,000 | $0.18 | $2.70K | 67,071 |
| Kate Rochlin Chief Operating Officer | Apr 30, 2025 | Option exercise | +12,295 | $0.18 | $2.21K | 55,169 |
| Alan S. Roemer Director | Apr 30, 2025 | Option exercise | +102,459 | $0.18 | $18.44K | 387,489 |
| Alan S. Roemer Director | Apr 30, 2025 | Option exercise | +11,000 | $0.18 | $1.98K | 398,489 |
| Patrick McCall CHIEF FINANCIAL OFFICER | Oct 4, 2024 | Award | +25,316 | – | – | 52,071 |
| Alan S. Roemer Director | Oct 4, 2024 | Award | +126,582 | – | – | 285,030 |
| Kate Rochlin Chief Operating Officer | Oct 4, 2024 | Award | +25,316 | – | – | 42,874 |
| Peter C. Brandt Director | Oct 4, 2024 | Award | +253,164 | – | – | 517,604 |
| William Tai-Wei Ho PRESIDENT AND CEO, Director, 10% owner | Oct 4, 2024 | Award | +126,582 | – | – | 2,548,094 |
| William Tai-Wei Ho President and CEO, Director, 10% owner | Dec 13, 2023 | Award | +81,967 | – | – | 2,421,512 |
| Lawrence Lamb EVP and CSO | Dec 13, 2023 | Award | +1,639 | – | – | 101,369 |
| Trishna Goswami Chief Medical Officer | Dec 13, 2023 | Award | +4,098 | – | – | 6,729 |
| Peter C. Brandt Director | Dec 13, 2023 | Award | +81,967 | – | – | 264,440 |
| Kate Rochlin Chief Operating Officer | Dec 13, 2023 | Award | +12,295 | – | – | 17,558 |
| Alan S. Roemer Director | Dec 13, 2023 | Award | +102,459 | – | – | 158,448 |
| Corinne Epperly Director | Dec 13, 2023 | Award | +81,967 | – | – | 81,967 |
| Jeremy R. Graff Director | Dec 13, 2023 | Award | +2,049 | – | – | 4,549 |
| Patrick McCall Chief Financial Officer | Dec 13, 2023 | Award | +20,492 | – | – | 26,755 |
| Jeremy R. Graff Director | Sep 13, 2023 | Buy | +2,500 | $0.95 | $2.38K | 2,500 |
| Patrick McCall Chief Financial Officer | Aug 25, 2023 | Buy | +1,000 | $1.03 | $1.03K | 6,263 |
| William Tai-Wei Ho President and CEO, Director, 10% owner | Aug 24, 2023 | Buy | +23,800 | $1.05 | $24.99K | 2,339,545 |
| Emily Fairbairn Director | Jul 28, 2023 | Other | −4,111,958 | – | – | 0 |
| Leslie W. Kreis Director, 10% owner | Dec 12, 2022 | Buy | +8,735 | $2.48 | $21.66K | 570,724 |
| Leslie W. Kreis Director, 10% owner | Dec 12, 2022 | Buy | +9,214 | $2.48 | $22.85K | 601,980 |
| Leslie W. Kreis Director, 10% owner | Dec 12, 2022 | Buy | +57,052 | $2.48 | $141.49K | 3,727,597 |
| BIOS Fund III QP, LP Director, 10% owner | Dec 12, 2022 | Buy | +8,735 | $2.48 | $21.66K | 570,724 |
| BIOS Fund III QP, LP Director, 10% owner | Dec 12, 2022 | Buy | +9,214 | $2.48 | $22.85K | 601,980 |
| BIOS Fund III QP, LP Director, 10% owner | Dec 12, 2022 | Buy | +57,052 | $2.48 | $141.49K | 3,727,597 |
| BIOS Fund II NT, LP Director, 10% owner | Sep 28, 2022 | Buy | +2,913 | $2.02 | $5.88K | 561,989 |
| BIOS Fund II NT, LP Director, 10% owner | Sep 28, 2022 | Buy | +19,017 | $2.02 | $38.41K | 3,670,545 |
| BIOS Fund II NT, LP Director, 10% owner | Sep 28, 2022 | Buy | +3,070 | $2.02 | $6.20K | 592,766 |
| Bios Equity Partners II, LP Director, 10% owner | Sep 28, 2022 | Buy | +2,913 | $2.02 | $5.88K | 561,989 |
| Bios Equity Partners II, LP Director, 10% owner | Sep 28, 2022 | Buy | +19,017 | $2.02 | $38.41K | 3,670,545 |
| Bios Equity Partners II, LP Director, 10% owner | Sep 28, 2022 | Buy | +3,070 | $2.02 | $6.20K | 592,766 |
| Cavu Advisors, LLC Director, 10% owner | Aug 29, 2022 | Buy | +4,660 | $2.02 | $9.41K | 559,076 |
| Cavu Advisors, LLC Director, 10% owner | Aug 29, 2022 | Buy | +4,912 | $2.02 | $9.92K | 589,696 |
| Cavu Advisors, LLC Director, 10% owner | Aug 29, 2022 | Buy | +30,428 | $2.02 | $61.46K | 3,651,528 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 29, 2022 | Buy | +4,660 | $2.02 | $9.41K | 559,076 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 29, 2022 | Buy | +4,912 | $2.02 | $9.92K | 589,696 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 29, 2022 | Buy | +30,428 | $2.02 | $61.46K | 3,651,528 |
| Cavu Advisors, LLC Director, 10% owner | Aug 26, 2022 | Buy | +1,377 | $2.01 | $2.77K | 584,784 |
| Cavu Advisors, LLC Director, 10% owner | Aug 26, 2022 | Buy | +8,531 | $2.01 | $17.15K | 3,621,100 |
| Cavu Advisors, LLC Director, 10% owner | Aug 26, 2022 | Buy | +1,306 | $2.01 | $2.63K | 554,416 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 26, 2022 | Buy | +1,377 | $2.01 | $2.77K | 584,784 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 26, 2022 | Buy | +8,531 | $2.01 | $17.15K | 3,621,100 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 26, 2022 | Buy | +1,306 | $2.01 | $2.63K | 554,416 |
| Cavu Management, LP Director, 10% owner | Aug 17, 2022 | Buy | +38,035 | $1.93 | $73.41K | 3,612,569 |
| Cavu Management, LP Director, 10% owner | Aug 17, 2022 | Buy | +5,823 | $1.93 | $11.24K | 553,110 |
| Cavu Management, LP Director, 10% owner | Aug 17, 2022 | Buy | +6,142 | $1.93 | $11.85K | 583,407 |
| BIOS Fund II NT, LP Director, 10% owner | Aug 17, 2022 | Buy | +5,823 | $1.93 | $11.24K | 553,110 |
| BIOS Fund II NT, LP Director, 10% owner | Aug 17, 2022 | Buy | +38,035 | $1.93 | $73.41K | 3,612,569 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.